Two rheumatoid arthritis drugs that suppress the i

Quote:

---

Two rheumatoid arthritis drugs that suppress the immune system may help critically ill patients survive covid-19, providing a benefit even on top of the steroids that have been doctors’ main tools in treating the most serious cases of illness, according to a new study released Thursday before peer review.

British regulators cited the new results as they promptly approved the two drugs , tocilizumab and sarilumab, for use in patients in intensive care units. The relative risk of death was reduced by 24 percent when given to people within 24 hours of admission, the data showed.

---

https://www.washingtonpost.com/health/2021/01...treatment/

Mmmmm, just to elaborate a little with this information while we wait for our data :

We know our CD-12 trial total death rate is 22.1% (87/390 deaths). To obtain a reduction of deaths of 24% (as in the U.K. trial) the split VX/SOC should be app. 52/35 (20.0% - 26.9% individually, 25.7% overall).

This means a p-value of 0.13348 and a ad-hoc Power of 34.3%.

So, a drug with a p-value of 0.1335 was approved in the U.K. !!!! Meaning: if we have 52 deaths we are in the same league as Tocilizumab and Sarilumab and, yes, should be approved. Of course, we are nor Regeneron or Sanofi, I you know what I mean ...

Another very important piece of information is that about 36 percent of patients died in the hospital who received standard care , while 28 percent died on tocilizumab and 22 percent died when given sarilumab.

Now, if this is the case (or similar) for our CD-12: Let's assume that the SOC deaths in our case was a smaller 33.1% (treatment is, overall better here). This means that VX cohort must be 16.9% (since we know that total must be 22.1%) this means a p-value of 0.0006486 and a stunning reduction of deaths of 48.8%!!!

All of the above just "translating" the numbers obtained by the anti-inflammatory drugs approved in U.K. to our trial.